Mechanisms in endocrinology. Bile acid sequestrants in type 2 diabetes: Potential effects on GLP1 secretion

European Journal of Endocrinology

Volumn 171, Issue 2, 2014, Pages

  Sonne, David P ^a   Hansen, Morten ^a   Knop, Filip K ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID SEQUESTRANT; CHENODEOXYCHOLIC ACID; CHOLECYSTOKININ; CHOLIC ACID; COLESEVELAM; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR 19; FORKHEAD TRANSCRIPTION FACTOR; FOX01 PROTEIN; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; TGR5 PROTEIN; UNCLASSIFIED DRUG; ALLYLAMINE; BILE ACID; CELL RECEPTOR; DRUG DERIVATIVE; FARNESOID X-ACTIVATED RECEPTOR; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; GPBAR1 PROTEIN, HUMAN;

BILE ACID METABOLISM; DRUG EFFECT; ENERGY EXPENDITURE; GALLBLADDER EMPTYING; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ENERGY METABOLISM; GLUCOSE BLOOD LEVEL; LIPID METABOLISM; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION (PROCESS);

ALLYLAMINE; ANIMALS; BILE ACIDS AND SALTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; FIBROBLAST GROWTH FACTORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; LIPID METABOLISM; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84905273290     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0154     Document Type: Review

References (238)

1. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ & Shan B. Identification of a nuclear receptor for bile acids. Science 1999 284 1362-1365. (doi:10.1126/science.284.5418.1362)
2. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999 284 1365-1368. (doi:10.1126/ science.284.5418.1365)
3. Wang H, Chen J, Hollister K, Sowers LC & Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Molecular Cell 1999 3 543-553. (doi:10.1016/S1097-2765(00)80348-2)
4. Trauner M & Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiological Reviews 2003 83 633-671. (doi:10.1152/physrev.00027.2002)
5. Claudel T, Staels B & Kuipers F. The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 2020-2030. (doi:10.1161/01.ATV.0000178994.21828.a7)
6. Lefebvre P, Cariou B, Lien F, Kuipers F & Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiological Reviews 2009 89 147-191. (doi:10.1152/physrev.00010.2008)
7. Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, Nakamura T, Itadani H & Tanaka K. Identification of membrane-type receptor for bile acids (M-BAR). Biochemical and Biophysical Research Communications 2002 298 714-719. (doi:10.1016/S0006-291X(02)02550-0)
8. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, Fukusumi S, Habata Y, Itoh T, Shintani Y et al. A G protein-coupled receptor responsive to bile acids. Journal of Biological Chemistry 2003 278 9435-9440. (doi:10.1074/jbc.M209706200)
9. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006 439 484-489. (doi:10.1038/nature04330)
10. Watanabe M, Morimoto K, Houten SM, Kaneko-Iwasaki N, Sugizaki T, Horai Y, Mataki C, Sato H, Murahashi K, Arita E et al. Bile acid binding resin improves metabolic control through the induction of energy expenditure. PLoS ONE 2012 7 e38286. (doi:10.1371/journal.pone.0038286)
11. Houten SM, Watanabe M & Auwerx J. Endocrine functions of bile acids. EMBO Journal 2006 25 1419-1425. (doi:10.1038/sj.emboj.7601049)
12. Katsuma S, Hirasawa A & Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochemical and Biophysical Research Communications 2005 329 386-390. (doi:10.1016/j.bbrc.2005.01.139)
13. Adrian TE, Gariballa S, Parekh KA, Thomas SA, Saadi H, Al Kaabi J, Nagelkerke N, Gedulin B & Young AA. Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers. Diabetologia 2012 55 2343-2347. (doi:10.1007/s00125-012- 2593-2)
14. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metabolism 2009 10 167-177. (doi:10.1016/j.cmet.2009.08.001)
15. Knop FK. Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes? American Journal of Physiology. Endocrinology and Metabolism 2010 299 E10-E13. (doi:10.1152/ajpendo. 00137.2010)
16. Garg A & Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Annals of Internal Medicine 1994 121 416-422. (doi:10.7326/0003-4819-121- 6-199409150-00004)
17. Zieve FJ, Kalin MF, Schwartz SL, Jones MR & Bailey WL. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clinical Therapeutics 2007 29 74-83. (doi:10.1016/j.clinthera.2007.01.003)
18. Suzuki T, Oba K, Igari Y, Matsumura N, Watanabe K, Futami-Suda S, Yasuoka H, Ouchi M, Suzuki K, Kigawa Y et al. Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. Journal of Nippon Medical School 2007 74 338-343. (doi:10.1272/jnms.74.338)
19. Jain AK, Stoll B, Burrin DG, Holst JJ & Moore DD. Enteral bile acid treatment improves parenteral nutrition-related liver disease and intestinal mucosal atrophy in neonatal pigs. American Journal of Physiology. Gastrointestinal and Liver Physiology 2012 302 G218-G224. (doi:10.1152/ajpgi. 00280.2011)
20. Roberts RE, Glicksman C, Alaghband-Zadeh J, Sherwood RA, Akuji N & le Roux CW. The relationship between postprandial bile acid concentration, GLP-1, PYY and ghrelin. Clinical Endocrinology 2011 74 67-72. (doi:10.1111/j.1365-2265. 2010.03886.x)
21. Patti M-E, Houten SM, Bianco AC, Bernier R, Larsen PR, Holst JJ, Badman MK, Maratos-Flier E, Mun EC, Pihlajamaki J et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity 2009 17 1671-1677. (doi:10.1038/oby.2009.102)
22. Beysen C, Murphy EJ, Deines K, Chan M, Tsang E, Glass A, Turner SM, Protasio J, Riiff T & Hellerstein MK. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia 2012 55 432-442. (doi:10.1007/s00125-011-2382-3)
23. Mcintyre N, Holdsworth CD & Turner DS. New interpretation of oral glucose tolerance. Lancet 1964 2 20-21. (doi:10.1016/S0140-6736(64)90011-X)
24. Perley MJ & Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. Journal of Clinical Investigation 1967 46 1954-1962. (doi:10.1172/JCI105685)
25. Nauck M, Stöckmann F, Ebert R & Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986 29 46-52. (doi:10.1007/BF02427280)
26. Holst JJ. The physiology of glucagon-like peptide 1. Physiological Reviews 2007 87 1409-1439. (doi:10.1152/physrev.00034.2006)
27. Ballantyne GH. Peptide YY(1-36) and peptide YY(3-36): Part I. Distribution, release and actions. Obesity Surgery 2006 16 651-658. (doi:10.1381/096089206776944959)
28. Theodorakis MJ, Carlson O, Michopoulos S, Doyle ME, Juhaszova M, Petraki K & Egan JM. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. American Journal of Physiology. Endocrinology and Metabolism 2006 290 E550-E559. (doi:10.1152/ajpendo.00326.2004)
29. Orskov C, Holst JJ & Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988 123 2009-2013. (doi:10.1210/endo-123-4-2009)
30. Christensen M, Vedtofte L, Holst JJ, Vilsbøll T & Knop FK. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 2011 60 3103-3109. (doi:10.2337/db11-0979)
31. Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG & Holst JJ. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 2003 88 2706-2713. (doi:10.1210/jc.2002- 021873)
32. Toft-Nielsen MB, Madsbad S & Holst JJ. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2001 86 3853-3860. (doi:10.1210/jcem.86.8.7743)
33. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J & Marks V. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. Journal of Endocrinology 1993 138 159-166. (doi:10.1677/joe.0.1380159)
34. Carr RD, Larsen MO, Winzell MS, Jelic K, Lindgren O, Deacon CF & Ahrén B. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. American Journal of Physiology. Endocrinology and Metabolism 2008 295 E779-E784. (doi:10.1152/ajpendo.90233.2008)
35. Rehfeld JF. Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides. Acta Physiologica 2011 201 405-411. (doi:10.1111/j.1748-1716.2010. 02235.x)
36. Gribble FM, Williams L, Simpson AK & Reimann F. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 2003 52 1147-1154. (doi:10.2337/diabetes.52.5. 1147)
37. Reimann F & Gribble FM. Glucose-sensing in glucagon-like peptide-1-secreting cells. Diabetes 2002 51 2757-2763. (doi:10.2337/diabetes.51. 9.2757)
38. Sugiyama K, Manaka H, Kato T, Yamatani K, Tominaga M & Sasaki H. Stimulation of truncated glucagon-like peptide-1 release from the isolated perfused canine ileum by glucose absorption. Digestion 1994 55 24-28. (doi:10.1159/000201118)
39. Gorboulev V, Schürmann A, Vallon V, Kipp H, Jaschke A, Klessen D, Friedrich A, Scherneck S, Rieg T, Cunard R et al. Na+-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 2012 61 187-196. (doi:10.2337/db11-1029)
40. Lauffer LM, Iakoubov R & Brubaker PL. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 2009 58 1058-1066. (doi:10.2337/db08-1237)
41. Hansen KB, Rosenkilde MM, Knop FK, Wellner N, Diep TA, Rehfeld JF, Andersen UB, Holst JJ & Hansen HS. 2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans. Journal of Clinical Endocrinology and Metabolism 2011 96 E1409-E1417. (doi:10.1210/jc.2011-0647)
42. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, Sugimoto Y, Miyazaki S & Tsujimoto G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nature Medicine 2005 11 90-94. (doi:10.1038/nm1168)
43. Edfalk S, Steneberg P & Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 2008 57 2280-2287. (doi:10.2337/db08-0307)
44. Samuel BS, Shaito A, Motoike T, Rey FE, Backhed F, Manchester JK, Hammer RE, Williams SC, Crowley J, Yanagisawa M et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. PNAS 2008 105 16767-16772. (doi:10.1073/pnas. 0808567105)
45. Karaki S, Mitsui R, Hayashi H, Kato I, Sugiya H, Iwanaga T, Furness JB & Kuwahara A. Short-chain fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestine. Cell and Tissue Research 2006 324 353-360. (doi:10.1007/s00441-005-0140-x)
46. Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, Cameron J, Grosse J, Reimann F & Gribble FM. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 2012 61 364-371. (doi:10.2337/db11-1019)
47. Gerspach AC, Steinert RE, Schönenberger L, Graber-Maier A & Beglinger C. The role of the gut sweet taste receptor in regulating GLP-1, PYY, and CCK release in humans. American Journal of Physiology. Endocrinology and Metabolism 2011 301 E317-E325. (doi:10.1152/ajpendo.00077.2011)
48. Steinert RE, Gerspach AC, Gutmann H, Asarian L, Drewe J & Beglinger C. The functional involvement of gut-expressed sweet taste receptors in glucose-stimulated secretion of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). Clinical Nutrition 2011 30 524-532. (doi:10.1016/j.clnu.2011.01.007)
49. Rozengurt N, Wu SV, Chen MC, Huang C, Sternini C & Rozengurt E. Colocalization of the α-subunit of gustducin with PYY and GLP-1 in L cells of human colon. American Journal of Physiology. Gastrointestinal and Liver Physiology 2006 291 G792-G802. (doi:10.1152/ajpgi.00074.2006)
50. Hansen L, Deacon CF, Orskov C & Holst JJ. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999 140 5356-5363. (doi:10.1210/endo.140.11.7143)
51. Rocca AS & Brubaker PL. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 1999 140 1687-1694. (doi:10.1210/endo.140.4.6643)
52. Hansen L, Hartmann B, Bisgaard T, Mineo H, Jørgensen PN & Holst JJ. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. American Journal of Physiology. Endocrinology and Metabolism 2000 278 E1010-E1018. (Pubitemid 30439137)
53. Orskov C, Holst JJ, Knuhtsen S, Baldissera FG, Poulsen SS & Nielsen OV. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 1986 119 1467-1475. (doi:10.1210/endo-119-4-1467)
54. Burhol PG, Lygren I, Waldum HL & Jorde R. The effect of duodenal infusion of bile on plasma VIP, GIP, and secretin and on duodenal bicarbonate secretion. Scandinavian Journal of Gasteroenterology 1980 15 1007-1011. (doi:10.3109/00365528009181805)
55. Flaten O, Hanssen LE, Osnes M & Myren J. Plasma concentrations of gastric inhibitory polypeptide after intraduodenal infusion of cattle bile and synthetic bile salts in man. Scandinavian Journal of Gasteroenterology 1981 16 1073-1075. (doi:10.3109/00365528109181031)
56. Namba M, Matsuyama T, Horie H, Nonaka K & Tarui S. Inhibition of pancreatic exocrine secretion and augmentation of the release of gut glucagon-like immunoreactive materials by intraileal administration of bile in the dog. Regulatory Peptides 1983 5 257-262. (doi:10.1016/0167-0115(83)90256-2)
57. Namba M, Matsuyama T, Itoh H, Imai Y, Horie H & Tarui S. Inhibition of pentagastrin-stimulated gastric acid secretion by intraileal administration of bile and elevation of plasma concentrations of gut glucagon-like immunoreactivity in anesthetized dogs. Regulatory Peptides 1986 15 121-128. (doi:10.1016/0167-0115(86)90082-0)
58. Namba M, Matsuyama T, Nonaka K & Tarui S. Effect of intraluminal bile or bile acids on release of gut glucagon-like immunoreactive materials in the dog. Hormone and Metabolic Research 1983 15 82-84. (doi:10.1055/s-2007-1018635)
59. Izukura M, Hashimoto T, Gomez G, Uchida T, Greeley GH Jr & Thompson JC. Intracolonic infusion of bile salt stimulates release of peptide YY and inhibits cholecystokinin-stimulated pancreatic exocrine secretion in conscious dogs. Pancreas 1991 6 427-432. (doi:10.1097/00006676-199107000-00009)
60. Gomez G, Lluis F, Ishizuka J, Draviam EJ, Uchida T, Greeley GH Jr & Thompson JC. Bile enhances release of insulin: an incretin-mediated effect. Surgery 1987 102 195-199. (Pubitemid 17158315)
61. Adrian TE, Ballantyne GH, Longo WE, Bilchik AJ, Graham S, Basson MD, Tierney RP & Modlin IM. Deoxycholate is an important releaser of peptide YY and enteroglucagon from the human colon. Gut 1993 34 1219-1224. (doi:10.1136/gut.34.9.1219)
62. Meyer-Gerspach AC, Steinert RE, Keller S, Malarski A, Schulte FH & Beglinger C. Effects of chenodeoxycholic acid on the secretion of gut peptides and fibroblast growth factors in healthy humans. Journal of Clinical Endocrinology and Metabolism 2013 98 3351-3358. (doi:10.1210/jc.2012-4109)
63. Murakami M, Une N, Nishizawa M, Suzuki S, Ito H & Horiuchi T. Incretin secretion stimulated by ursodeoxycholic acid in healthy subjects. SpringerPlus 2013 2 20. (doi:10.1186/2193-1801-2-20)
64. Wu T, Bound MJ, Standfield SD, Gedulin B, Jones KL, Horowitz M & Rayner CK. Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans. Diabetes, Obesity & Metabolism 2013 15 474-477. (doi:10.1111/dom.12043)
65. Vedtofte L, Bodvarsdottir TB, Gotfredsen CF, Karlsen AE, Knudsen LB & Heller RS. Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus. Regulatory Peptides 2010 160 106-114. (doi:10.1016/j.regpep.2009.12.005)
66. Borg CM, le Roux CW, Ghatei MA, Bloom SR, Patel AG & Aylwin SJB. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. British Journal of Surgery 2006 93 210-215. (doi:10.1002/bjs.5227)
67. Laferrère B, Heshka S, Wang K, Khan Y, McGinty J, Teixeira J, Hart AB & Olivan B. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 2007 30 1709-1716. (doi:10.2337/dc06-1549)
68. Le Roux CW, Aylwin SJB, Batterham RL, Borg CM, Coyle F, Prasad V, Shurey S, Ghatei MA, Patel AG & Bloom SR. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Annals of Surgery 2006 243 108-114. (doi:10.1097/01.sla.0000183349. 16877.84)
69. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K & Schoelles K. Bariatric surgery: a systematic review and meta-analysis. Journal of the American Medical Association 2004 292 1724-1737. (doi:10.1001/jama.292. 14.1724)
70. Pournaras DJ, Aasheim ET, Søvik TT, Andrews R, Mahon D, Welbourn R, Olbers T & le Roux CW. Effect of the definition of type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders. British Journal of Surgery 2012 99 100-103. (doi:10.1002/bjs.7704)
71. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annual Review of Biochemistry 2003 72 137-174. (doi:10.1146/annurev.biochem.72. 121801.161712)
72. Norlin M & Wikvall K. Enzymes in the conversion of cholesterol into bile acids. Current Molecular Medicine 2007 7 199-218. (doi:10.2174/ 156652407780059168)
73. Rous P & McMaster PD. The concentrating activity of the gall bladder. Journal of Experimental Medicine 1921 34 47-73. (doi:10.1084/jem.34.1.47)
74. Dietschy JM. Water and solute movement across the wall of the rabbit gall bladder. Gastroenterology 1964 47 395-408.
75. Wheeler HO. Concentrating function of the gallbladder. American Journal of Medicine 1971 51 588-595. (doi:10.1016/0002-9343(71)90283-X)
76. Russell DW. Fifty years of advances in bile acid synthesis and metabolism. Journal of Lipid Research 2009 50 (Suppl) S120-S125. (doi:10.1194/jlr.R800026-JLR200)
77. Inagaki T, Moschetta A, Lee Y-K, Peng L, Zhao G, Downes M, Yu RT, Shelton JM, Richardson JA, Repa JJ et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. PNAS 2006 103 3920-3925. (doi:10.1073/pnas.0509592103)
78. Hofmann AF & Eckmann L. How bile acids confer gut mucosal protection against bacteria. PNAS 2006 103 4333-4334. (doi:10.1073/pnas.0600780103)
79. Hofmann AF & Hagey LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cellular and Molecular Life Sciences 2008 65 2461-2483. (doi:10.1007/s00018-008-7568-6)
80. Thomas C, Pellicciari R, Pruzanski M, Auwerx J & Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nature Reviews. Drug Discovery 2008 7 678-693. (doi:10.1038/nrd2619)
81. Prawitt J, Caron S & Staels B. Bile acid metabolism and the pathogenesis of type 2 diabetes. Current Diabetes Reports 2011 11 160-166. (doi:10.1007/s11892-011-0187-x)
82. Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, Noonan DJ, Burka LT, McMorris T, Lamph WW et al. Identification of a nuclear receptor that is activated by farnesolmetabolites. Cell 1995 81 687-693. (doi:10.1016/0092- 8674(95)90530-8)
83. Chiang JYL. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocrine Reviews 2002 23 443-463. (doi:10.1210/er.2000-0035)
84. Pircher PC, Kitto JL, Petrowski ML, Tangirala RK, Bischoff ED, Schulman IG & Westin SK. Farnesoid X receptor regulates bile acid-amino acid conjugation. Journal of Biological Chemistry 2003 278 27703-27711. (doi:10.1074/jbc.M302128200)
85. Moschetta A, Bookout AL &Mangelsdorf DJ. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nature Medicine 2004 10 1352-1358. (doi:10.1038/nm1138)
86. Zhang JH, Nolan JD, Kennie SL, Johnston IM, Dew T, Dixon PH, Williamson C & Walters JRF. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. American Journal of Physiology. Gastrointestinal and Liver Physiology 2013 304 G940-G948. (doi:10.1152/ajpgi. 00398.2012)
87. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metabolism 2005 2 217-225. (doi:10.1016/j.cmet.2005.09.001)
88. Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, Donahee M, Wang DY, Mansfield TA, Kliewer SA et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes and Development 2003 17 1581-1591. (doi:10.1101/gad.1083503)
89. Lin BC, Wang M, Blackmore C & Desnoyers LR. Liver-specific activities of FGF19 require Klotho β. Journal of Biological Chemistry 2007 282 27277-27284. (doi:10.1074/jbc.M704244200)
90. Gupta S, Stravitz RT, Dent P & Hylemon PB. Down-regulation of cholesterol 7α-hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway. Journal of Biological Chemistry 2001 276 15816-15822. (doi:10.1074/jbc. M010878200)
91. Zhang J, Huang W, Qatanani M, Evans RM & Moore DD. The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity. Journal of Biological Chemistry 2004 279 49517-49522. (doi:10.1074/jbc.M409041200)
92. Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. PNAS 2001 98 3369-3374. (doi:10.1073/pnas.051551698)
93. Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, Haussler MR & Mangelsdorf DJ. Vitamin D receptor as an intestinal bile acid sensor. Science 2002 296 1313-1316. (doi:10.1126/science.1070477)
94. Hofmann AF. Detoxification of lithocholic acid, a toxic bile acid: relevance to drug hepatotoxicity. Drug Metabolism Reviews 2004 36 703-722. (doi:10.1081/DMR-200033475)
95. Qiao L, Studer E, Leach K, McKinstry R, Gupta S, Decker R, Kukreja R, Valerie K, Nagarkatti P, El Deiry W et al. Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis. Molecular Biology of the Cell 2001 12 2629-2645. (doi:10.1091/mbc.12.9.2629)
96. Raufman JP, Zimniak P & Bartoszko-Malik A. Lithocholyltaurine interacts with cholinergic receptors on dispersed chief cells from guinea pig stomach. American Journal of Physiology 1998 274 G997-1004.
97. Raufman J-P, Chen Y, Zimniak P & Cheng K. Deoxycholic acid conjugates are muscarinic cholinergic receptor antagonists. Pharmacology 2002 65 215-221. (doi:10.1159/000064347)
98. Le Y, Murphy PM & Wang JM. Formyl-peptide receptors revisited. Trends in Immunology 2002 23 541-548. (doi:10.1016/S1471-4906(02)02316-5)
99. Ferrari C, Macchiarulo A, Costantino G & Pellicciari R. Pharmacophore model for bile acids recognition by the FPR receptor. Journal of Computer-Aided Molecular Design 2006 20 295-303. (doi:10.1007/s10822-006-9055-1)
100. Keitel V, Cupisti K, Ullmer C, Knoefel WT, Kubitz R & Häussinger D. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology 2009 50 861-870. (doi:10.1002/hep.23032)
101. Vassileva G, Golovko A, Markowitz L, Abbondanzo SJ, Zeng M, Yang S, Hoos L, Tetzloff G, Levitan D, Murgolo NJ et al. Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. Biochemical Journal 2006 398 423-430. (doi:10.1042/BJ20060537)
102. Li T, Holmstrom SR, Kir S, Umetani M, Schmidt DR, Kliewer SA & Mangelsdorf DJ. The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. Molecular Endocrinology 2011 25 1066-1071. (doi:10.1210/me.2010-0460)
103. Keitel V, Reinehr R, Gatsios P, Rupprecht C, Görg B, Selbach O, Häussinger D & Kubitz R. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology 2007 45 695-704. (doi:10.1002/hep.21458)
104. Keitel V, Donner M, Winandy S, Kubitz R & Häussinger D. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochemical and Biophysical Research Communications 2008 372 78-84. (doi:10.1016/j.bbrc.2008.04.171)
105. Maruyama T, Tanaka K, Suzuki J, Miyoshi H, Harada N, Nakamura T, Miyamoto Y, Kanatani A & Tamai Y. Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. Journal of Endocrinology 2006 191 197-205. (doi:10.1677/joe.1.06546)
106. Poole DP, Godfrey C, Cattaruzza F, Cottrell GS, Kirkland JG, Pelayo JC, Bunnett NW & Corvera CU. Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system. Neurogastroenterology and Motility 2010 22 814-825, e227-228. (doi:10.1111/j.1365-2982.2010.01487.x)
107. Alemi F, Poole DP, Chiu J, Schoonjans K, Cattaruzza F, Grider JR, Bunnett NW & Corvera CU. The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology 2013 144 145-154. (doi:10.1053/j.gastro.2012.09.055)
108. Kumar DP, Rajagopal S, Mahavadi S, Mirshahi F, Grider JR, Murthy KS & Sanyal AJ. Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic β cells. Biochemical and Biophysical Research Communications 2012 427 600-605. (doi:10.1016/j.bbrc.2012.09.104)
109. Fu L, John LM, Adams SH, Yu XX, Tomlinson E, Renz M, Williams PM, Soriano R, Corpuz R, Moffat B et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004 145 2594-2603. (doi:10.1210/en.2003-1671)
110. Watanabe M, Horai Y, Houten SM, Morimoto K, Sugizaki T, Arita E, Mataki C, Sato H, Tanigawara Y, Schoonjans K et al. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. Journal of Biological Chemistry 2011 286 26913-26920. (doi:10.1074/jbc.M111.248203)
111. Brufau G, Bahr MJ, Staels B, Claudel T, Ockenga J, Böker KH, Murphy EJ, Prado K, Stellaard F, Manns MP et al. Plasma bile acids are not associated with energy metabolism in humans. Nutrition and Metabolism 2010 7 73. (doi:10.1186/1743-7075-7-73)
112. Ockenga J, Valentini L, Schuetz T, Wohlgemuth F, Glaeser S, Omar A, Kasim E, duPlessis D, Featherstone K, Davis JR et al. Plasma bile acids are associated with energy expenditure and thyroid function in humans. Journal of Clinical Endocrinology and Metabolism 2012 97 535-542. (doi:10.1210/jc.2011- 2329)
113. Koike K, Murakami K, Nozaki N, Sugiura K & Inoue M. Colestilan, a new bile acid-sequestering resin, reduces bodyweight in postmenopausal women who have dieted unsuccessfully. Drugs in R&D 2005 6 273-279. (doi:10.2165/00126839-200506050-00003)
114. Nakatani H, Kasama K, Oshiro T, Watanabe M, Hirose H & Itoh H. Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery. Metabolism: Clinical and Experimental 2009 58 1400-1407. (doi:10.1016/j.metabol.2009.05.006)
115. Simonen M, Dali-Youcef N, Kaminska D, Venesmaa S, Käkelä P, Pääkkönen M, Hallikainen M, Kolehmainen M, Uusitupa M, Moilanen L et al. Conjugated bile acids associate with altered rates of glucose and lipid oxidation after Roux-en-Y gastric bypass. Obesity Surgery 2012 22 1473-1480. (doi:10.1007/s11695-012-0673-5)
116. Insull W Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. Southern Medical Journal 2006 99 257-273. (doi:10.1097/01.smj.0000208120.73327.db)
117. Donovan JM, Von Bergmann K, Setchell KDR, Isaacsohn J, Pappu AS, Illingworth DR, Olson T & Burke SK. Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Digestive Diseases and Sciences 2005 50 1232-1238. (doi:10.1007/s10620-005-2765-8)
118. Einarsson K, Ericsson S, Ewerth S, Reihner E, Rudling M, Ståhlberg D & Angelin B. Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism. European Journal of Clinical Pharmacology 1991 40 53-58. (doi:10.1007/BF03216291)
119. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. Journal of the American Medical Association 1984 251 351-364. (doi:10.1001/jama.1984.03340270029025)
120. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. Journal of the American Medical Association 1984 251 365-374. (doi:10.1001/jama.1984.03340270043026)
121. Brufau G, Stellaard F, Prado K, Bloks VW, Jonkers E, Boverhof R, Kuipers F & Murphy EJ. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 2010 52 1455-1464. (doi:10.1002/hep.23831)
122. Garbutt JT & Kenney TJ. Effect of cholestyramine on bile acid metabolism in normal man. Journal of Clinical Investigation 1972 51 2781-2789. (doi:10.1172/JCI107100)
123. Einarsson K, Hellström K & Kallner M. The effect of cholestyramine on the elimination of cholesterol as bile acids in patients with hyperlipoproteinaemia type II and IV. European Journal of Clinical Investigation 1974 4 405-410. (doi:10.1111/j.1365-2362.1974.tb00413.x)
124. Angelin B, Björkhem I, Einarsson K & Ewerth S. Cholestyramine treatment reduces postprandial but not fasting serum bile acid levels in humans. Gastroenterology 1982 83 1097-1101. (Pubitemid 12028487)
125. Aldridge MA & Ito MK. Colesevelam hydrochloride: a novel bile acid-binding resin. Annals of Pharmacotherapy 2001 35 898-907. (doi:10.1345/aph.10263)
126. Benson GM, Haynes C, Blanchard S & Ellis D. In vitro studies to investigate the reasons for the low potency of cholestyramine and colestipol. Journal of Pharmaceutical Sciences 1993 82 80-86. (doi:10.1002/jps.2600820118)
127. Braunlin WH, Holmes-Farley SR, Smisek D, Guo A, Appruzese W, Xu QW, Hook P, Zhorov E & Mandeville H. In vitro comparison of bile acid-binding to colesevelam hydrochloride and other bile acid sequestrants. Abstracts of Papers of the American Chemical Society 2000 219 U409-U410.
128. Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, Burton D, Carlson P, Busciglio IA, Lamsam J, Singh R & Zinsmeister AR. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clinical Gastroenterology and Hepatology 2010 8 159-165.e5. (doi:10.1016/j.cgh.2009.10.020)
129. Marcus SN & Heaton KW. Intestinal transit, deoxycholic acid and the cholesterol saturation of bile - three inter-related factors. Gut 1986 27
130. Marina AL, Utzschneider KM, Wright LA, Montgomery BK, Marcovina SM & Kahn SE. Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and β-cell function. Diabetes Care 2012 35 1119-1125. (doi:10.2337/dc11-2050)
131. Bennion LJ & Grundy SM. Effects of diabetes mellitus on cholesterol metabolism in man. New England Journal of Medicine 1977 296 1365-1371. (doi:10.1056/NEJM197706162962401)
132. Hassan AS, Subbiah MT & Thiebert P. Specific changes of bile acid metabolism in spontaneously diabetic Wistar rats. Proceedings of the Society for Experimental Biology and Medicine 1980 164 449-452. (doi:10.3181/00379727-164- 40894)
133. Nervi FO, Severín CH & Valdivieso VD. Bile acid pool changes and regulation of cholate synthesis in experimental diabetes. Biochimica et Biophysica Acta 1978 529 212-223. (doi:10.1016/0005-2760(78)90064-4)
134. Uchida K, Makino S & Akiyoshi T. Altered bile acid metabolism in nonobese, spontaneously diabetic (NOD) mice. Diabetes 1985 34 79-83. (doi:10.2337/diab.34.1.79)
135. Li T, Francl JM, Boehme S, Ochoa A, Zhang Y, Klaassen CD, Erickson SK & Chiang JYL. Glucose and insulin induction of bile acid synthesis: mechanisms and implication in diabetes and obesity. Journal of Biological Chemistry 2012 287 1861-1873. (doi:10.1074/jbc.M111.305789)
136. De Leon MP, Ferenderes R & Carulli N. Bile lipid composition and bile acid pool size in diabetes. American Journal of Digestive Diseases 1978 23 710-716. (doi:10.1007/BF01072357)
137. Abrams JJ, Ginsberg H & Grundy SM. Metabolism of cholesterol and plasma triglycerides in nonketotic diabetes mellitus. Diabetes 1982 31 903-910. (doi:10.2337/diab.31.10.903)
138. Andersén E, Karlaganis G & Sjövall J. Altered bile acid profiles in duodenal bile and urine in diabetic subjects. European Journal of Clinical Investigation 1988 18 166-172. (doi:10.1111/j.1365-2362.1988.tb02408.x)
139. Haber GB & Heaton KW. Lipid composition of bile in diabetics and obesity-matched controls. Gut 1979 20 518-522. (doi:10.1136/gut.20.6.518)
140. Haeusler RA, Astiarraga B, Camastra S, Accili D & Ferrannini E. Human insulin resistance is associated with increased plasma levels of 12α-hydroxylated bile acids. Diabetes 2013 62 4184-4191. (doi:10.2337/db13-0639)
141. Duran-Sandoval D, Mautino G, Martin G, Percevault F, Barbier O, Fruchart J-C, Kuipers F & Staels B. Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 2004 53 890-898. (doi:10.2337/diabetes.53.4.890)
142. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA & Kahn CR. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Molecular Cell 2000 6 87-97. (doi:10.1016/S1097-2765(00)00010-1)
143. Twisk J, Hoekman MF, Lehmann EM, Meijer P, Mager WH & Princen HM. Insulin suppresses bile acid synthesis in cultured rat hepatocytes by down-regulation of cholesterol 7α-hydroxylase and sterol 27-hydroxylase gene transcription. Hepatology 1995 21 501-510.
144. Andersén E, Hellström P & Hellström K. Cholesterol biosynthesis in nonketotic diabetics before and during insulin therapy. Diabetes Research and Clinical Practice 1987 3 207-214. (doi:10.1016/S0168-8227(87) 80041-4)
145. Staels B & Fonseca VA. Bile acids and metabolic regulation. Diabetes Care 2009 32 S237-S245. (doi:10.2337/dc09-S355)
146. Haeusler RA, Pratt-Hyatt M, Welch CL, Klaassen CD & Accili D. Impaired generation of 12-hydroxylated bile acids links hepatic insulin signaling with dyslipidemia. Cell Metabolism 2012 15 65-74. (doi:10.1016/j.cmet. 2011.11.010)
147. Chiang JYL. Bile acids: regulation of synthesis. Journal of Lipid Research 2009 50 1955-1966. (doi:10.1194/jlr.R900010-JLR200)
148. Suhre K, Meisinger C, Döring A, Altmaier E, Belcredi P, Gieger C, Chang D, Milburn MV, Gall WE, Weinberger KM et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS ONE 2010 5 e13953. (doi:10.1371/journal.pone.0013953)
149. Shaham O, Wei R, Wang TJ, Ricciardi C, Lewis GD, Vasan RS, Carr SA, Thadhani R, Gerszten RE & Mootha VK. Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Molecular Systems Biology 2008 4 214. (doi:10.1038/msb.2008.50)
150. Zhao X, Peter A, Fritsche J, Elcnerova M, Fritsche A, Häring H-U, Schleicher ED, Xu G & Lehmann R. Changes of the plasma metabolome during an oral glucose tolerance test: is there more than glucose to look at? American Journal of Physiology. Endocrinology and Metabolism 2009 296 E384-E393. (doi:10.1152/ajpendo.90748.2008)
151. Cani PD & Delzenne NM. The role of the gut microbiota in energy metabolism andmetabolic disease. Current Pharmaceutical Design 2009 15 1546-1558. (doi:10.2174/138161209788168164)
152. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012 490 55-60. (doi:10.1038/nature11450)
153. Bays HE, Goldberg RB, Truitt KE & Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Archives of Internal Medicine 2008 168 1975-1983. (doi:10.1001/archinte.168.18.1975)
154. Fonseca VA, Rosenstock J, Wang AC, Truitt KE & Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008 31 1479-1484. (doi:10.2337/dc08-0283)
155. Goldberg RB, Fonseca VA, Truitt KE & Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Archives of Internal Medicine 2008 168 1531-1540. (doi:10.1001/archinte.168.14.1531)
156. Yamakawa T, Takano T, Utsunomiya H, Kadonosono K & Okamura A. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocrine Journal 2007 54 53-58. (doi:10.1507/endocrj.K05- 098)
157. Rosenstock J, Hernandez-Triana E, Handelsman Y, Misir S, Jones M & Nagendran S. Initial combination therapy with metformin plus colesevelam in drug-naïve hispanic patients with early type 2 diabetes. Postgraduate Medicine 2012 124 7-13. (doi:10.3810/pgm.2012.07.2560)
158. Rosenstock J, Hernandez-Triana E, Handelsman Y, Misir S & Jones MR. Clinical effects of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetes. Postgraduate Medicine 2012 124 14-20. (doi:10.3810/pgm.2012. 07.2564)
159. Bays HE. Long-term (52-78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012 5 125-134. (doi:10.2147/DMSO. S32018)
160. Thomson AB. Diabetes and intestinal cholesterol uptake from bile salt solutions. Canadian Journal of Physiology and Pharmacology 1987 65 856-860. (doi:10.1139/y87-137)
161. Van Dijk TH, Grefhorst A, Oosterveer MH, Bloks VW, Staels B, Reijngoud D-J & Kuipers F. An increased flux through the glucose 6-phosphate pool in enterocytes delays glucose absorption in Fxr-/- mice. Journal of Biological Chemistry 2009 284 10315-10323. (doi:10.1074/jbc.M807317200)
162. Schwartz SL, Lai Y-L, Xu J, Abby SL, Misir S, Jones MR & Nagendran S. The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study. Metabolic Syndrome and Related Disorders 2010 8 179-188. (doi:10.1089/met.2009.0049)
163. Matsuda M & DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999 22 1462-1470. (doi:10.2337/diacare.22.9.1462)
164. Henry RR, Aroda VR, Mudaliar S, Garvey WT, Chou HS & Jones MR. Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus. Diabetes, Obesity & Metabolism 2012 14 40-46. (doi:10.1111/j.1463-1326.2011.01486.x)
165. Handelsman Y, Goldberg RB, Garvey WT, Fonseca VA, Rosenstock J, Jones MR, Lai Y-L, Jin X, Misir S, Nagendran S et al. Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. Endocrine Practice 2010 16 617-628. (doi:10.4158/EP10129.OR)
166. Mazze RS, Strock ES, Monk AM, Murphy MM, Xi M & Bergenstal RM. Diurnal glucose profilesusing continuous glucosemonitoring toidentify the glucose-lowering characteristics of colesevelam HCL (Welchol). Endocrine Practice 2013 19 275-283. (doi:10.4158/EP12337.OR)
167. Smushkin G, Sathananthan M, Piccinini F, Dalla Man C, Law JH, Cobelli C, Zinsmeister AR, Rizza RA & Vella A. The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes. Diabetes 2013 62 1094-1101. (doi:10.2337/db12-0923)
168. Duran-Sandoval D, Cariou B, Percevault F, Hennuyer N, Grefhorst A, van Dijk TH, Gonzalez FJ, Fruchart J-C, Kuipers F & Staels B. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. Journal of Biological Chemistry 2005 280 29971-29979. (doi:10.1074/jbc.M501931200)
169. Ma K, Saha PK, Chan L & Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. Journal of Clinical Investigation 2006 116 1102-1109. (doi:10.1172/JCI25604)
170. Stayrook KR, Bramlett KS, Savkur RS, Ficorilli J, Cook T, Christe ME, Michael LF & Burris TP. Regulation of carbohydratemetabolism by the farnesoid X receptor. Endocrinology 2005 146 984-991. (doi:10.1210/en.2004-0965)
171. Yamagata K, Daitoku H, Shimamoto Y, Matsuzaki H, Hirota K, Ishida J & Fukamizu A. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. Journal of Biological Chemistry 2004 279 23158-23165. (doi:10.1074/jbc.M314322200)
172. Cariou B, Chetiveaux M, Zaïr Y, Pouteau E, Disse E, Guyomarc'h-Delasalle B, Laville M & Krempf M. Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults. Nutrition and Metabolism 2011 8 48. (doi:10.1186/1743-7075-8-48)
173. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM & Edwards PA. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. PNAS 2006 103 1006-1011. (doi:10.1073/pnas. 0506982103)
174. Shen H, Zhang Y, Ding H, Wang X, Chen L, Jiang H & Shen X. Farnesoid X receptor induces GLUT4 expression through FXR response element in the GLUT4 promoter. Cellular Physiology and Biochemistry 2008 22 1-14. (doi:10.1159/000149779)
175. Fabiani ED, Mitro N, Gilardi F, Caruso D, Galli G & Crestani M. Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. Journal of Biological Chemistry 2003 278 39124-39132. (doi:10.1074/jbc.M305079200)
176. Koo S-H, Satoh H, Herzig S, Lee C-H, Hedrick S, Kulkarni R, Evans RM, Olefsky J & Montminy M. PGC-1 promotes insulin resistance in liver through PPAR-α-dependent induction of TRB-3. Nature Medicine 2004 10 530-534. (doi:10.1038/nm1044)
177. Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A, Abdelkarim M, Caron S, Torpier G, Fruchart J-C, Gonzalez FJ et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. Journal of Biological Chemistry 2006 281 11039-11049. (doi:10.1074/jbc. M510258200)
178. Popescu IR, Helleboid-Chapman A, Lucas A, Vandewalle B, Dumont J, Bouchaert E, Derudas B, Kerr-Conte J, Caron S, Pattou F et al. The nuclear receptor FXR is expressed in pancreatic β-cells and protects human islets from lipotoxicity. FEBS Letters 2010 584 2845-2851. (doi:10.1016/j.febslet.2010. 04.068)
179. Renga B, Mencarelli A, Vavassori P, Brancaleone V & Fiorucci S. The bile acid sensor FXR regulates insulin transcription and secretion. Biochimica et Biophysica Acta 2010 1802 363-372. (doi:10.1016/j.bbadis.2010.01.002)
180. Angelin B, Larsson TE & Rudling M. Circulating fibroblast growth factors as metabolic regulators - a critical appraisal. Cell Metabolism 2012 16 693-705. (doi:10.1016/j.cmet.2012.11.001)
181. Zweers SJLB, Booij KAC, Komuta M, Roskams T, Gouma DJ, Jansen PLM & Schaap FG. The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology 2012 55 575-583. (doi:10.1002/hep.24702)
182. Tomlinson E, Fu L, John L, Hultgren B, Huang X, Renz M, Stephan JP, Tsai SP, Powell-Braxton L, French D et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002 143 1741-1747. (doi:10.1210/endo.143.5.8850)
183. Potthoff MJ, Boney-Montoya J, Choi M, He T, Sunny NE, Satapati S, Suino-Powell K, Xu HE, Gerard RD, Finck BN et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. Cell Metabolism 2011 13 729-738. (doi:10.1016/j.cmet.2011.03.019)
184. Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, Xu HE, Shulman GI, Kliewer SA & Mangelsdorf DJ. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 2011 331 1621-1624. (doi:10.1126/science.1198363)
185. Shin D-J & Osborne TF. FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action. Journal of Biological Chemistry 2008 284 11110-11120. (doi:10.1074/jbc.M808747200)
186. Barutcuoglu B, Basol G, Cakir Y, Cetinkalp S, Parildar Z, Kabaroglu C, Ozmen D, Mutaf I & Bayindir O. Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome. Annals of Clinical and Laboratory Science 2011 41 390-396.
187. Stejskal D, Karpísek M, Hanulová Z & Stejskal P. Fibroblast growth factor-19: development, analytical characterization and clinical evaluation of a new ELISA test. Scandinavian Journal of Clinical and Laboratory Investigation 2008 68 501-507. (doi:10.1080/00365510701854967)
188. Schreuder TCMA, Marsman HA, Lenicek M, van Werven JR, Nederveen AJ, Jansen PLM & Schaap FG. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. American Journal of Physiology. Gastrointestinal and Liver Physiology 2010 298 G440-G445. (doi:10.1152/ajpgi.00322.2009)
189. Jansen PLM, van Werven J, Aarts E, Berends F, Janssen I, Stoker J & Schaap FG. Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery. Digestive Diseases 2011 29 48-51. (doi:10.1159/000324128)
190. Pournaras DJ, Glicksman C, Vincent RP, Kuganolipava S, Alaghband-Zadeh J, Mahon D, Bekker JHR, Ghatei MA, Bloom SR, Walters JRF et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology 2012 153 3613-3619. (doi:10.1210/en.2011-2145)
191. Nicholes K, Guillet S, Tomlinson E, Hillan K, Wright B, Frantz GD, Pham TA, Dillard-Telm L, Tsai SP, Stephan J-P et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. American Journal of Pathology 2002 160 2295-2307. (doi:10.1016/S0002-9440(10)61177-7)
192. Vrieze A, Holleman F, Zoetendal EG, de Vos WM, Hoekstra JBL & Nieuwdorp M. The environment within: how gut microbiota may influence metabolism and body composition. Diabetologia 2010 53 606-613. (doi:10.1007/s00125-010- 1662-7)
193. Kootte RS, Vrieze A, Holleman F, Dallinga-Thie GM, Zoetendal EG, de Vos WM, Groen AK, Hoekstra JBL, Stroes ES & Nieuwdorp M. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes, Obesity & Metabolism 2012 14 112-120. (doi:10.1111/j.1463-1326.2011.01483.x)
194. Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JFWM, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012 143 913-916e7. (doi:10.1053/j.gastro.2012.06.031)
195. Chen L, McNulty J, Anderson D, Liu Y, Nystrom C, Bullard S, Collins J, Handlon AL, Klein R, Grimes A et al. Cholestyramine reverses hyperglycemia and enhances glucose-stimulated glucagon-like peptide 1 release in Zucker diabetic fatty rats. Journal of Pharmacology and Experimental Therapeutics 2010 334 164-170. (doi:10.1124/jpet.110.166892)
196. Shang Q, Saumoy M, Holst JJ, Salen G & Xu G. Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. American Journal of Physiology. Gastrointestinal and Liver Physiology 2010 298 G419-G424. (doi:10.1152/ajpgi.00362.2009)
197. Harach T, Pols TWH, Nomura M, Maida A, Watanabe M, Auwerx J & Schoonjans K. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Scientific Reports 2012 2 430. (doi:10.1038/srep00430)
198. Potthoff MJ, Potts A, He T, Duarte JAG, Taussig R, Mangelsdorf DJ, Kliewer SA & Burgess SC. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. American Journal of Physiology. Gastrointestinal and Liver Physiology 2013 304 G371-G380. (doi:10.1152/ajpgi.00400.2012)
199. Garg SK, Ritchie PJ, Moser EG, Snell-Bergeon JK, Freson BJ & Hazenfield RM. Effects of colesevelam on LDL-C, A1c and GLP-1 levels in patients with type 1 diabetes: a pilot randomized double-blind trial. Diabetes, Obesity & Metabolism 2011 13 137-143. (doi:10.1111/j.1463-1326.2010.01320.x)
200. Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ & Gribble FM. Glucose sensing in L cells: a primary cell study. Cell Metabolism 2008 8 532-539. (doi:10.1016/j.cmet.2008.11.002)
201. Pellicciari R, Sato H, Gioiello A, Costantino G, Macchiarulo A, Sadeghpour BM, Giorgi G, Schoonjans K & Auwerx J. Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23-and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5. Journal of Medicinal Chemistry 2007 50 4265-4268. (doi:10.1021/jm070633p)
202. Sato H, Macchiarulo A, Thomas C, Gioiello A, Une M, Hofmann AF, Saladin R, Schoonjans K, Pellicciari R & Auwerx J. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. Journal of Medicinal Chemistry 2008 51 1831-1841. (doi:10.1021/jm7015864)
203. Parker HE, Wallis K, le Roux CW, Wong KY, Reimann F & Gribble FM. Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. British Journal of Pharmacology 2012 165 414-423. (doi:10.1111/j.1476-5381.2011.01561.x)
204. Eissele R, Göke R, Willemer S, Harthus HP, Vermeer H, Arnold R & Göke B. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. European Journal of Clinical Investigation 1992 22 283-291. (doi:10.1111/j.1365-2362.1992.tb01464.x)
205. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM & Bloom SR. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985 89 1070-1077. (Pubitemid 16231572)
206. Larsson LI, Holst J, Håkanson R & Sundler F. Distribution and properties of glucagon immunoreactivity in the digestive tract of various mammals: an immunohistochemical and immunochemical study. Histochemistry 1975 44 281-290. (doi:10.1007/BF00490364)
207. Sato M, Shibata C, Kikuchi D, Ikezawa F, Imoto H & Sasaki I. Effects of biliary and pancreatic juice diversion into the ileum on gastrointestinal motility and gut hormone secretion in conscious dogs. Surgery 2010 148 1012-1019. (doi:10.1016/j.surg.2010.03.007)
208. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER & Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006 444 1027-1031. (doi:10.1038/nature05414)
209. Hofmann AF. Bile acid sequestrants improve glycemic control in type 2 diabetes: a proposed mechanism implicating glucagon-like peptide 1 release. Hepatology 2011 53 1784. (doi:10.1002/hep.24100)
210. Poley JR & Hofmann AF. Role of fat maldigestion in pathogenesis of steatorrhea in ileal resection. Fat digestion after two sequential test meals with and without cholestyramine. Gastroenterology 1976 71 38-44.
211. Knoebel LK. Intestinal absorption in vivo of micellar and nonmicellar lipid. American Journal of Physiology 1972 223 255-261.
212. Ross SA & Shaffer EA. The importance of triglyceride hydrolysis for the release of gastric inhibitory polypeptide. Gastroenterology 1981 80 108-111.
213. Beglinger S, Drewe J, Schirra J, Goke B, D'Amato M & Beglinger C. Role of fat hydrolysis in regulating glucagon-like peptide-1 secretion. Journal of Clinical Endocrinology and Metabolism 2010 95 879-886. (doi:10.1210/jc.2009- 1062)
214. Rehfeld JF. The new biology of gastrointestinal hormones. Physiological Reviews 1998 78 1087-1108. (Pubitemid 28491949)
215. Koide M, Okabayashi Y & Otsuki M. Role of endogenous bile on basal and postprandial CCK release in humans. Digestive Diseases and Sciences 1993 38 1284-1290. (doi:10.1007/BF01296080)
216. Gomez G, Upp JR Jr, Lluis F, Alexander RW, Poston GJ, Greeley GH Jr & Thompson JC. Regulation of the release of cholecystokinin by bile salts in dogs and humans. Gastroenterology 1988 94 1036-1046.
217. Kogire M, Gomez G, Uchida T, Ishizuka J, Greeley GH Jr & Thompson JC. Chronic effect of oral cholestyramine, a bile salt sequestrant, and exogenous cholecystokinin on insulin release in rats. Pancreas 1992 7 15-20. (doi:10.1097/00006676-199201000-00003)
218. Hildebrand P, Ensinck JW, Ketterer S, Delco F, Mossi S, Bangerter U & Beglinger C. Effect of a cholecystokinin antagonist on meal-stimulated insulin and pancreatic polypeptide release in humans. Journal of Clinical Endocrinology and Metabolism 1991 72 1123-1129. (doi:10.1210/jcem-72-5-1123)
219. Schwarzendrube J, Niederau M, Lüthen R & Niederau C. Effects of cholecystokinin-receptor blockade on pancreatic and biliary function in healthy volunteers. Gastroenterology 1991 100 1683-1690.
220. Ahrén B, Holst JJ & Efendic S. Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2000 85 1043-1048. (doi:10.1210/jcem.85.3.6431)
221. Rushakoff RJ, Goldfine ID, Carter JD & Liddle RA. Physiological concentrations of cholecystokinin stimulate amino acid-induced insulin release in humans. Journal of Clinical Endocrinology and Metabolism 1987 65 395-401. (doi:10.1210/jcem-65-3-395)
222. Reimers J, Nauck M, Creutzfeldt W, Strietzel J, Ebert R, Cantor P & Hoffmann G. Lack of insulinotropic effect of endogenous and exogenous cholecystokinin in man. Diabetologia 1988 31 271-280.
223. Fieseler P, Bridenbaugh S, Nustede R, Martell J, Orskov C, Holst JJ & Nauck MA. Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8. American Journal of Physiology 1995 268 E949-E955.
224. Brubaker PL. Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides. Endocrinology 1991 128 3175-3182. (doi:10.1210/endo-128-6-3175)
225. Dumoulin V, Dakka T, Plaisancie P, Chayvialle JA & Cuber JC. Regulation of glucagon-like peptide-1-(7-36) amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum. Endocrinology 1995 136 5182-5188. (doi:10.1210/endo.136.11. 7588257)
226. Plaisancie P, Bernard C, Chayvialle JA & Cuber JC. Regulation of glucagon-like peptide-1-(7-36) amide secretion by intestinal neurotransmitters and hormones in the isolated vascularly perfused rat colon. Endocrinology 1994 135 2398-2403. (doi:10.1210/endo.135.6.7988423)
227. Roberge JN & Brubaker PL. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 1993 133 233-240. (doi:10.1210/endo.133.1.8319572)
228. Niederau C, Heintges T, Rovati L & Strohmeyer G. Effects of loxiglumide on gallbladder emptying in healthy volunteers. Gastroenterology 1989 97 1331-1336. (Pubitemid 19258723)
229. Lieverse RJ, Jansen JB, Jebbink MC, Masclee AA, Rovati LC & Lamers CB. Effects of somatostatin and loxiglumide on gallbladder motility. European Journal of Clinical Pharmacology 1995 47 489-492. (doi:10.1007/BF00193699)
230. Portincasa P, Peeters TL, van Berge-Henegouwen GP, van Solinge WW, Palas-ciano G & van Erpecum KJ. Acute intraduodenal bile salt depletion leads to strong gallbladder contraction, altered antroduodenal motility and high plasma motilin levels in humans. Neurogastroenterology and Motility 2000 12 421-430. (doi:10.1046/j.1365-2982. 2000.00217.x)
231. Palasciano G, Portincasa P, Belfiore A, Baldassarre G & Albano O. Opposite effects of cholestyramine and loxiglumide on gallbladder dynamics in humans. Gastroenterology 1992 102 633-639.
232. Sonne DP, Hare KJ, Martens P, Rehfeld JF, Holst JJ, Vilsbøll T & Knop FK. Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients. American Journal of Physiology. Gastrointestinal and Liver Physiology 2013 304 G413-G419. (doi:10.1152/ajpgi.00435.2012)
233. Egerod KL, Engelstoft MS, Grunddal KV, Nøhr MK, Secher A, Sakata I, Pedersen J, Windeløv JA, Füchtbauer E-M, Olsen J et al. A major lineage of enteroendocrine cells coexpress CCK, secretin, GIP, GLP-1, PYY, and neurotensin but not somatostatin. Endocrinology 2012 153 5782-5795. (doi:10.1210/en.2012-1595)
234. Lavoie B, Balemba OB, Godfrey C, Watson CA, Vassileva G, Corvera CU, Nelson MT & Mawe GM. Hydrophobic bile salts inhibit gallbladder smooth muscle function via stimulation of GPBAR1 receptors and activation of KATP channels. Journal of Physiology 2010 588 3295-3305. (doi:10.1113/jphysiol.2010. 192146)
235. Yang JI, Yoon J-H, Myung SJ, Gwak G-Y, Kim W, Chung GE, Lee SH, Lee S-M, Kim CY & Lee H-S. Bile acid-induced TGR5-dependent c-Jun-N terminal kinase activation leads to enhanced caspase 8 activation in hepatocytes. Biochemical and Biophysical Research Communications 2007 361 156-161. (doi:10.1016/j.bbrc. 2007.07.001)
236. Yasuda H, Hirata S, Inoue K, Mashima H, Ohnishi H & Yoshiba M. Involvement of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. Biochemical and Biophysical Research Communications 2007 354 154-159. (doi:10.1016/j.bbrc.2006.12.168)
237. Hong J, Behar J, Wands J, Resnick M, Wang LJ, DeLellis RA, Lambeth D, Souza RF, Spechler SJ & Cao W. Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma. Gut 2010 59 170-180. (doi:10.1136/gut.2009.188375)
238. Poupon R. Bile acid mimetic-activated TGR5 receptor in metabolic-related liver disorder: the good and the bad. Gastroenterology 2010 138 1207-1209. (doi:10.1053/j.gastro.2010.01.029)